WallStreetZenWallStreetZen

NASDAQ: CABA
Cabaletta Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for CABA

Based on 6 analysts offering 12 month price targets for Cabaletta Bio Inc.
Min Forecast
$25.00+46.54%
Avg Forecast
$34.50+102.23%
Max Forecast
$50.00+193.08%

Should I buy or sell CABA stock?

Based on 6 analysts offering ratings for Cabaletta Bio Inc.
Strong Buy
Strong Buy
5 analysts 83.33%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CABA stock forecasts and price targets.

CABA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-22
lockedlocked$00.00+00.00%2024-03-22Find Out Why
lockedlocked$00.00+00.00%2024-03-22
lockedlocked$00.00+00.00%2024-02-05
lockedlocked$00.00+00.00%2023-11-29
Stifel Nicolaus
Top 22%
79
Strong BuyInitiates Coverage On$31.00+81.71%2023-10-19

1 of 1

Forecast return on equity

Is CABA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.27%

Forecast return on assets

Is CABA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CABA revenue forecast

What is CABA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$194.3M
Avg 2 year Forecast
$231.5M
Avg 3 year Forecast
$688.3M

CABA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CABA$17.06$34.50+102.23%Strong Buy
AVTE$29.57$65.00+119.82%Strong Buy
HLVX$16.63$30.67+84.41%Strong Buy
PRAX$61.02$103.00+68.80%Strong Buy
PRME$7.00$18.75+167.86%Strong Buy

Cabaletta Bio Stock Forecast FAQ

Is Cabaletta Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CABA) stock is to Strong Buy CABA stock.

Out of 6 analysts, 5 (83.33%) are recommending CABA as a Strong Buy, 1 (16.67%) are recommending CABA as a Buy, 0 (0%) are recommending CABA as a Hold, 0 (0%) are recommending CABA as a Sell, and 0 (0%) are recommending CABA as a Strong Sell.

If you're new to stock investing, here's how to buy Cabaletta Bio stock.

What is CABA's revenue growth forecast for 2027-2029?

(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Cabaletta Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2027 to be $9,373,345,795, with the lowest CABA revenue forecast at $9,373,345,795, and the highest CABA revenue forecast at $9,373,345,795. On average, 3 Wall Street analysts forecast CABA's revenue for 2028 to be $11,169,188,154, with the lowest CABA revenue forecast at $1,683,632,364, and the highest CABA revenue forecast at $29,249,856,007.

In 2029, CABA is forecast to generate $33,203,738,772 in revenue, with the lowest revenue forecast at $12,142,414,496 and the highest revenue forecast at $54,265,063,049.

What is CABA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CABA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CABA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CABA price target, the average CABA price target is $34.50, with the highest CABA stock price forecast at $50.00 and the lowest CABA stock price forecast at $25.00.

On average, Wall Street analysts predict that Cabaletta Bio's share price could reach $34.50 by Mar 22, 2025. The average Cabaletta Bio stock price prediction forecasts a potential upside of 102.23% from the current CABA share price of $17.06.

What is CABA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CABA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.